June 6, 2017Open Access

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

As compared with crizotinib, alectinib showed superior efficacy and lower toxicity in primary treatment of ALK-positive NSCLC. (Funded by F. Hoffmann-La Roche; ALEX ClinicalTrials.gov number, NCT02075840 .).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Solange Peters

D. Ross Camidge

Alice T. Shaw

Journals

New England Journal of Medicine

Actions

Institutions

University of Michigan

Massachusetts General Hospital

University of California, Irvine

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study